Bristol-Myers Squibb Company BMY
62.91 USD +0.11 (+0.18%)
At closeNov 11, 2026, 6:16 PM EST
63.29 +0.38 +0.61%
After hours · Nov 11, 6:16 PM ET
61.31 Day range 62.96
45.27 52-week range 68.64
- YTD
- +16.63%
- 1 year
- +29.13%
News
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.
defenseworld.net Bristol Myers Squibb Company $BMY Holdings Trimmed by AEGON ASSET MANAGEMENT UK Plc AEGON ASSET MANAGEMENT UK Plc trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 6.3% during the undefined quarter, according to its most recent disclosure with the…
zacks.com Will Bristol Myers' Growth Brands Offset Eliquis Headwinds? Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.
247wallst.com 5 Defensive Dividend Stocks Yielding Up to 8.7% for Retirement Income Recessions punish shaky payouts, but some companies keep collecting cash anyway. From power lines to pipelines to pill bottles, five low-beta names promise income, yet one of them runs coverage…
benzinga.com Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.
fool.com Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors The average pharmaceutical stock yields 1.4%, while Bristol Myers Squibb yields 4%. Bristol Myers Squibb is working through a transition period as older drugs lose patent protection.
fool.com Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027? Bristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances. Vertex Pharmaceuticals…
benzinga.com Bristol Myers Squibb Presents 56-Week Results From Phase 3 SCOUT-HCM Clinical Trial In Late-Breaker Presentation At HCMS Scientific Sessions With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the first approved treatment for pediatric patients ≥30…
businesswire.com Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos.
247wallst.com Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027? A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know which numbers…
fool.com 3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market They are so much more than just dividend stocks.
defenseworld.net 48,234 Shares in Bristol Myers Squibb Company $BMY Acquired by Associated Banc Corp Associated Banc Corp bought a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
youtube.com 3 of the Best Dividend Stocks to Own These dividend stocks with economic moats offer durable payouts.
zacks.com Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
benzinga.com Tempus AI Says It Is Uniquely Positioned Tempus AI stock rises after beating Q3 earnings estimates and securing $192.5 million in data deals with Bristol Myers Squibb and Pathos.
benzinga.com Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40 Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.
benzinga.com Bristol-Myers Squibb Says AI Is Already Speeding Up Drug Research — And It's Measuring The Impact Bristol-Myers beats Q3 2026 estimates with $13.07B in revenue and raises full-year sales guidance driven by newer drug growth.
benzinga.com Bristol-Myers Squibb Q3 2026 Earnings Call Transcript Bristol-Myers Squibb (NYSE:BMY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Bristol-Myers Squibb Lowers FY2026 Adj EPS Guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 Est; Raises FY2026 Sales Guidance from $49.000B-$50.000B to $49.750B-$50.250B vs $49.886B Est Bristol-Myers Squibb (NYSE:BMY) lowers FY2026 Adj EPS guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 analyst estimate. Raises FY2026 sales outlook from $49.000 billion-$50.000 billion to $49.750…
benzinga.com Bristol-Myers Squibb Q3 Adj. EPS $1.35 Beats $1.17 Estimate, Sales $13.069B Beat $12.738B Estimate Bristol-Myers Squibb (NYSE:BMY) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.17 by 15.38 percent. This is a 17.18 percent decrease over earnings of…
benzinga.com Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings Amazon, Intel, Sandisk and six other stocks report earnings Thursday. See implied moves, analyst estimates and the billions in market value at stake.
benzinga.com Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
benzinga.com Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78 Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.
benzinga.com Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC Late-breaking results to be presented in an oral presentation at ESMO 2026PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this…
benzinga.com What's Going On with Bristol Myers Squibb Stock on Friday? Bristol Myers Squibb releases trial results for their multiple sclerosis CAR T therapy and Phase 3 breast cancer conjugate candidate.- benzinga.com Bristol Myers Squibb Presents Interim Safety, Efficacy Data From Its Multiple Sclerosis Groups Of Phase 1 Trial Of Zolacabtagene Autoleucel At MSToronto 2026 Bristol Myers Squibb (NYSE:BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2…
benzinga.com Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Oncology Portfolio Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world multimodal datasets. Connected…- benzinga.com SystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026 Late-breaking results to be presented in an oral presentation at ESMO 2026With two positive Phase 3 trials in breast cancer, these data reinforce the potential of iza-bren to further redefine…
- benzinga.com BioNTech To Present New Clinical Data From Its Late-Stage Oncology Pipeline With 16 Abstracts At European Society For Medical Oncology, October 23–27; Key Oral Presentations Will Focus On Clinical Data For Pumitamig Plus Docetaxel In Second-Line Metastatic Non-Small Cell Lung Cancer Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60 Wells Fargo analyst Mohit Bansal maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight and lowers the price target from $65 to $60.
benzinga.com Why Is Contineum Therapeutics Stock Falling Monday? BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential for PIPE-791 in IPF.
benzinga.com Why Is Bristol Myers Squibb Stock Gaining Monday? Bristol Myers Squibb stock jumped over 4% after positive Phase 3 results for neuroendocrine tumors and pulmonary fibrosis treatments.- benzinga.com Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By Blinded Independent Central Review, And Safety Results Consistent With Known Safety Profile Bristol Myers Squibb (NYSE:BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb…
- benzinga.com Bristol Myers Squibb's Admilparant Meets Phase 3 Primary Endpoint in Idiopathic Pulmonary Fibrosis Trial In the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51% Bristol Myers Squibb reports positive Phase 3 trial data, showing ZENBEXUS cuts the multiple myeloma progression risk by 51%.- benzinga.com Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53 Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.
benzinga.com Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.- benzinga.com Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41 Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.
- benzinga.com Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59 Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.
- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED) Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.
benzinga.com This $3 Biotech Could Be Worth $11.45, Analyst Says William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety in active psoriatic arthritis.
benzinga.com Bristol Myers Squibb Announces Two-Year Results From Its Phase 3 POETYK PSA-2 Study Showing Durable Efficacy And A Consistent Safety Profile For Sotyktu In Adults With Active Psoriatic Arthritis; Data Build On The Proven Efficacy And Safety Of Sotyktu These data are being presented at the Congress of Clinical Rheumatology - West (CCR-West) in Huntington Beach, California, taking place September 17-20, 2026.Among patients who entered the OLE,…- benzinga.com Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82 Piper Sandler analyst David Amsellem reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $75 to $82.
benzinga.com HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65 HSBC analyst Rajesh Kumar maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $60 to $65.
benzinga.com Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients Bristol Myers Squibb reported positive Phase 2 results for its arlo-cel therapy, meeting key endpoints for multiple myeloma patients.